TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01901341

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01183923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alfalfa Sprouts
Description: Alfalfa sprouts will be eaten daily in a sandwich form during the intervention period for alfalfa sprouts.
Study: NCT03666377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: 1 piece of sugarless gum to be chewed three times daily for 1 hour each.
Study: NCT04521348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Description: Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Description: Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Description: Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: multiple tyrosine kinase inhibitor(mTKI) Combined with anti-PD-1 antibody
Description: Patients receive Multiple Target Kinase Inhibitor(mTKI) Combined with Anti-Programmed Death-1(PD-1) Antibody
Study: NCT01851499

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ultramicronized PEA (Normast)
Description: 600 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ultramicronized PEA (Normast)
Description: 600 mg
Study: NCT03848013

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q switched Nd YAG laser
Description: Laser device emitting Q switched Nd YAG aiming for skin toning

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser
Description: Laser device emitting fractionated ablative laser aiming for skin resurfacing
Study: NCT00962403

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga treatment
Description: The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
Study: NCT04392661

Intervention type: PROCEDURE
Intervention: Laparoscopic Sleeve Gastrectomy
Description: bariatric surgeries and data collection
Study: NCT01627548

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Approach Therapy
Description: The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Approach Therapy
Description: The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
Study: NCT00630916

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Mitroflow Aortic Heart Valve
Description: Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
Study: NCT01556217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39393406
Description: Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
Study: NCT04656990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Intervention
Description: Gross motor and social-emotional integrated intervention
Study: NCT03874611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrophysiological data from DBS
Description: For each selected patient, the evaluation of cognitive or sensory-motor functions by electrophysiology will be conducted in the operating room, preoperatively the week before implantation and post-operatively within five days between the implantation of deep electrodes and the setting of the stimulator.
Study: NCT00406055

Intervention type: DEVICE
Intervention: RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6
Description: Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
Study: NCT02389582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran
Description: Use for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Use for 5 days
Study: NCT01658332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 3 tubes (15 ml)
Study: NCT00942136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Suspension as a single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
Study: NCT02456896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
Study: NCT00627692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 0.5 mg o.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.
Study: NCT02907229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NCVC-CS1
Description: Intervention Description
Study: NCT00997893

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy Phytoestrogen
Description: Novasoy® pill (55 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Estradiol pill (1 mg)
Study: NCT03464136

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo for Ustekinumab
Description: Participants will receive placebo as SC injection to blind adalimumab.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Adalimumab
Description: Participants will receive placebo as IV infusion to blind ustekinumab.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab (6 mg/kg)
Description: Participants will receive ustekinumab 6 mg/kg (weight based dosing) as IV infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg)
Description: Participants will self-administer SC injection of ustekinumab 90 mg.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab (40 mg)
Description: Participants will self-administer multiple SC injections of adalimumab (each 40 mg) and will receive total dose of 160 mg at Week 0, 80 mg at Week 2, and 40 mg q2w from Week 4 to 56.
Study: NCT01751347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Local anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Local anesthetics
Study: NCT03500848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus will be started between 3 and 7 days post-transplantation and continued after randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The tacrolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. Tacrolimus trough levels are targeted to be maintained at 8-15ng/ml until Month 6. After Month 6, the dose will be adjusted over time to maintain steady-state tacrolimus trough blood levels of approximately 5-10 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tacrolimus elimination)
Description: Tacrolimus will be started between 3 and 7 days post-transplantation at a dose of 1.0 mg twice a day (bid, 2 mg daily dose) for 30 (± 5) days and eliminated when randomization is done.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Within 24 hours of randomization, sirolimus will be started at a dose of 2.0 mg once a day. The sirolimus trough level is measured twice a week for 1 month, followed by trough level once a month thereafter. The dose will be adjusted over time to maintain steady-state sirolimus trough blood levels of approximately 4-10 ng/mL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF and/or steroids
Description: For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF and/or steroids
Description: For patients in both groups, MMF and/or steroids are initiated at or prior to the time of liver transplantation according to local practice. Steroids reduction is encouraged by 3 months post liver transplantation.
Study: NCT02347670

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy-patient navigator to improve follow-up adherence
Description: Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy-patient navigator to improve follow-up adherence
Description: Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Efficacy-patient navigator to improve follow-up adherence
Description: Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office-Based Usual Care
Description: Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.~This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital.
Study: NCT05308043

Intervention type: DIAGNOSTIC_TEST
Intervention: Deep learning algorism
Description: A deep learning algorism that was developed previous would be applied to identify retinoblastoma tumours on Retcam images and distinguish between active and inactive retinoblastoma tumours. The decision of two different senior ophthalmologists would be the gold standard.
Study: NCT02437149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Power Point
Description: Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Brochure with the National Highway Traffic Safety Administration information about distracting driving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Brochure with the National Highway Traffic Safety Administration information about distracting driving.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brochure
Description: Brochure with the National Highway Traffic Safety Administration information about distracting driving.
Study: NCT00868309

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anavip
Description: Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CroFab
Description: CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
Study: NCT03165565

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)
Description: Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Care
Description: Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
Study: NCT03137563

Intervention type: OTHER
Intervention: questionnaire
Description: The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
Study: NCT00349947

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Program
Description: Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
Study: NCT05231109

Intervention type: OTHER
Group type: OTHER
Intervention: vestibular rehabilitation
Description: Vestibular rehabilitation consisted of a total of 12 sessions, rearranged every 15 days. These exercises were prepared gradually to increase the vestibulo-ocular reflex and vestibulospinal reflex. The following exercises were done with the patients: vestibular adaptation exercises, oculo-motor exercises, standing by changing the support area, the support surface and the arm positions, heel-toe walking, walking with head rotation, backward walking, counting on a soft surface with eyes open and closed, and dynamic balance exercises were taught to the patients. The therapist gave the patients a home exercise program. It was emphasized that the exercises should be applied as 10 repetitions. After the session, the exercises shown to the patients were explained in written form and given as home exercises. They were also asked to do home exercises 3 times a day, 10 repetitions, for 15 days. Patients were re-evaluated before the treatment, at the 3rd month and after the 6th month.
Study: NCT04957108

Intervention type: OTHER
Intervention: Device identification using Xray.
Description: PMIDa and CRMD-f applications were used to identify CIED
Study: NCT02287168

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-gastrectomy peritoneal washing cytology
Description: sampling of peritoneal washing fluid before gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pre-gastrectomy peritoneal washing cytology
Description: sampling of peritoneal washing fluid before gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-gastrectomy peritoneal washing cytology
Description: sampling of peritoneal washing fluid after gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-gastrectomy peritoneal washing cytology
Description: sampling of peritoneal washing fluid after gastrectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: post-lavage peritoneal washing cytology
Description: sampling of peritoneal washing fluid after peritoneal lavage
Study: NCT02276196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: GLP-1 receptor agonist

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glulisine
Description: Insulin analogue
Study: NCT04259840

Intervention type: OTHER
Intervention: Observation
Description: Soft tissue implant measurements
Study: NCT01506830

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Relative isolation with cotton rolls
Description: Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation with rubber dam
Description: Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
Study: NCT00041574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Description: Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
Study: NCT01202006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training of general practitioners in an uptitration protocol.
Description: The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
Study: NCT02396381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.2
Description: Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Ad libitum use of CC in an ambulatory setting for 26 weeks